Kanaph Therapeutics Inc. (0082N0)

Overview

Kanaph Therapeutics Inc. is a pioneering biotechnology company dedicated to the discovery and development of next-generation therapeutics aimed at treating oncology and autoimmune diseases. Founded in 2019 and headquartered in Seoul, South Korea, the company employs a cutting-edge disease-signature-based drug discovery platform alongside advanced bioinformatics technologies. This innovative approach allows for the creation of treatments that specifically address critical unmet medical needs arising from solid tumors and immune-related disorders.

Central to Kanaph's strategy is its focus on advancing preclinical programs through strategic partnerships and a self-sustaining research and development model. This model ensures continuous pipeline expansion and momentum towards clinical progression in its therapeutic offerings.

Products and Services

• Bispecific Antibodies

  Kanaph's oncology pipeline includes bispecific antibodies targeting FAP (Fibroblast Activation Protein) and IL-12R (Interleukin 12 Receptor) for the treatment of solid tumors, such as non-small cell lung cancer. These antibodies are designed to enhance the immune response within the tumor microenvironment, promoting effective tumor eradication.

• Small Molecule Inhibitors

  The company also develops small molecule inhibitors like SHP2 and SOS1, which target various neoplasms. These inhibitors work by modulating specific intracellular signaling pathways to inhibit tumor growth and promote apoptosis in cancer cells.

• Antibody-Drug Conjugates (ADCs)

  Kanaph's ADCs, such as EGFR x c-Met bispecifics, represent a novel therapeutic approach for targeting specific cancer cells. These conjugates deliver cytotoxic agents directly to tumor cells, minimizing damage to surrounding healthy tissue while ensuring maximum efficacy in tumor destruction.

• Bispecific Fc-Fusion Proteins

  In the realm of autoimmune conditions, Kanaph develops bispecific Fc-fusion proteins, including C3 x VEGF, aimed at targeting diabetic neuropathies and macular edema. These proteins inhibit the alternative complement pathway and angiogenesis while regulating downstream complement activation, providing a multifaceted approach to treating complex autoimmune diseases.